|
|
Vaccine Detail
|
HLA-Matched Donor Mononuclear Cell-Enriched Leukocytes Apocell Vaccine |
| Vaccine Information |
- Vaccine Name: HLA-Matched Donor Mononuclear Cell-Enriched Leukocytes Apocell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Product Name: Apocell
- Vaccine Ontology ID: VO_0007437
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: PAEP
- PAEP
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A preparation of allogeneic HLA-matched leukocytes treated with a derivative of placental protein 14 (PP14) with potential immunomodulating activity. PP14 derivative-treated HLA-matched donor mononuclear cell-enriched leukocytes contain at least fifty-five percent early-apoptotic T cells; after infusion and when processed by recipient dendritic cells, early-apoptotic T cells may help induce a decrease in the donor effector T-cell responses against the recipient of an allogeneic hematopoietic stem cell (HSC) transplant, thereby minimizing allogeneic HSC transplant-related graft-versus-host disease (GVHD). PP14, a 162 amino acid glycosylated protein secreted by the late secretory phase endometrium, binds to T cells in a carbohydrate fashion and has been shown to induce T-cell apoptosis; maternal immune tolerance to the fetus and pregnancy-related remissions of autoimmune disease may involve PP14-induced T cell apoptosis. (NCIT_C71162).
|
| Host Response |
|
|
| References |
NCIT_C71162: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71162]
|
|
